Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053)

Antimicrob Agents Chemother. 1992 Aug;36(8):1773-8. doi: 10.1128/AAC.36.8.1773.

Abstract

Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy. Foscarnet clearance in plasma averaged (+/- standard deviation) 0.16 +/- 0.03 and 0.13 +/- 0.05 liter/h/kg of body weight in the absence and presence of ZDV. ZDV parameters were also not significantly altered, with a mean (+/- standard deviation) oral clearance of 2.7 +/- 1.0 and 2.6 +/- 0.8 liter/h/kg for the 2 study days, respectively.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy
  • Acquired Immunodeficiency Syndrome / metabolism*
  • Adult
  • Antiviral Agents / pharmacokinetics*
  • Antiviral Agents / therapeutic use
  • Chromatography, High Pressure Liquid
  • Drug Interactions
  • Foscarnet / pharmacokinetics*
  • Foscarnet / therapeutic use
  • HIV Core Protein p24 / analysis
  • HIV Core Protein p24 / immunology
  • Humans
  • Male
  • Middle Aged
  • Zidovudine / pharmacokinetics*
  • Zidovudine / therapeutic use

Substances

  • Antiviral Agents
  • HIV Core Protein p24
  • Foscarnet
  • Zidovudine